Immunic (NASDAQ:IMUX) Now Covered by William Blair

William Blair initiated coverage on shares of Immunic (NASDAQ:IMUX) in a research report report published on Tuesday, MarketBeat.com reports. The firm issued an outperform rating on the stock.

Several other analysts have also recently commented on the company. D. Boral Capital restated a “buy” rating and set a $17.00 target price on shares of Immunic in a report on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Immunic in a research report on Friday, February 21st. Finally, StockNews.com cut shares of Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $12.67.

Immunic Price Performance

NASDAQ IMUX opened at $1.25 on Tuesday. The stock’s 50 day simple moving average is $1.07 and its 200 day simple moving average is $1.21. Immunic has a one year low of $0.92 and a one year high of $2.11. The firm has a market cap of $112.60 million, a PE ratio of -1.02 and a beta of 1.89.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Invesco Ltd. acquired a new stake in shares of Immunic during the 4th quarter worth approximately $37,000. Virtu Financial LLC bought a new position in Immunic in the third quarter valued at approximately $50,000. HB Wealth Management LLC bought a new position in Immunic in the fourth quarter valued at approximately $81,000. Barclays PLC acquired a new stake in Immunic during the 4th quarter worth $84,000. Finally, Jane Street Group LLC raised its position in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after acquiring an additional 38,553 shares during the last quarter. 51.82% of the stock is currently owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.